Cargando empresa
Just reported
Q3 2026 results
From Editas Medicine's results release of 9 de noviembre de 2026; its quarterly report has since been filed.
Revenue
Actual
10,4M US$
+37 % y/y
-13 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,15 US$
Guided
—
No guide given
Operating income, GAAP
Actual
-24,3M US$
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.48B US$A+
EXELExelixis, Inc.17,3B US$A+
JAZZJazz Pharmaceuticals plc15,9B US$A
HALOHalozyme Therapeutics, Inc.11,6B US$A+
TECHBIO-Techne Corp11,4B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 oct 2026BAGraded B, now A
Cómo gana dinero
- Licensing and research collaborations100 %
Los porcentajes de ingresos son estimaciones para FY2025, no cifras de un informe oficial.
Compite con
- CRSPCRISPR TherapeuticsF
- Tamaño
- 4,5B US$
- Margen
- -1812,1 %
- BEAMBeam TherapeuticsF
- Tamaño
- 2,7B US$
- Margen
- -73,9 %
- NTLAIntellia TherapeuticsD
- Tamaño
- 1,6B US$
- Margen
- -805,7 %
- VRTXVertex PharmaceuticalsB
- Tamaño
- 138,7B US$
- Margen
- 30,7 %
- AMGNAmgenA
- Tamaño
- 253,2B US$
- Margen
- 24,1 %
- REGNRegeneron PharmaceuticalsC
- Tamaño
- 101,3B US$
- Margen
- 28,5 %
Qué vende3
EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.
Quién se lo compra3
- Bristol Myers Squibb: collaborates on research into gene-edited immune-cell treatments and may make milestone and royalty payments.
- Vertex Pharmaceuticals: licenses Editas gene-editing technology for medicines targeting inherited blood disorders and pays annual license fees.
- Immatics: collaborates with Editas on gene-edited immune-cell treatments for cancer.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1The business depends heavily on EDIT-401, its lead medicine, and on advancing it from preclinical research into human trials.
- 2Editas licenses important gene-editing patents from universities and research institutions; those agreements require payments and compliance with their terms.
- 3It relies on outside manufacturers and service providers for research materials and planned clinical trials, and on partners and investors for funding.
Qué podría salir mal
- 1EDIT-401 has not yet established safety or effectiveness in people; failure or delay in its development could significantly affect the business.
- 2Gene-editing patents and licenses are subject to disputes and challenges, which could limit Editas's rights to use or license important technology.
- 3Editas has no medicine-sale revenue and needs substantial funding; if it cannot raise money or receive partner payments, it may have to cut or delay research and development.
Estados financieros completos →
Sobre Editas Medicine, Inc.
Editas develops medicines that change deoxyribonucleic acid (DNA) to treat disease. Its CRISPR (clustered regularly interspaced short palindromic repeats) technology uses a guide molecule to direct an enzyme to a chosen DNA location. Its lead medicine, EDIT-401, is being prepared for early human testing to lower low-density lipoprotein (LDL) cholesterol; the company also licenses its technology and works with drug companies on research programs.
- Sede
- Cambridge, Massachusetts
- Fundada en
- 2013
- Cotiza en
- Nasdaq
- Cierre del ejercicio
- December 31
Construido a partir de los propios informes de Editas Medicine, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
